Serum Metabolome Alterations in Patients with Nonalcoholic Fatty Liver Disease

Published: 19 November 2021| Version 1 | DOI: 10.17632/x9frhhy7d4.1
Contributor:
Xuemei Wang

Description

Supplementary Data S1: In the negative mode the raw data of metabolites of all participants (149NAFLD and 149HCs). Supplementary Data S2: In the positive mode the raw data of metabolites of all participants (149NAFLD and 149HCs). Supplementary Data S3: Metabolites detected(100NAFLD and 100HCs) in the negative mode in the training set. Supplementary Data S4: Metabolites detected in the positive mode in the training set(100NAFLD and 100HCs). Supplementary Data S5: Differential metabolites between NAFLDs and healthy controls in discovery set. Supplementary Data S6: Differential metabolites between NAFLDs and healthy controls in validation set. Supplementary Data S7: Calculated data for volcanic maps. Supplementary Data S8: Metabolite classification analysis. Supplementary Data S9:metabolites correlation coefficient. Supplementary Data S10:p-value of metabolites. Supplementary Data S11:Brite A of KEGG brite Database. Supplementary Data S12:Brite B of KEGG brite Database. Supplementary Data S13:Brite C of KEGG brite Database. Supplementary Data S14:KEGG metabolic pathway information sheet. Supplementary Data S15:Results of differential metabolite KEGG enrichment analysis. Supplementary Data S16:Results of KEGG pathway topological analysis of the differential metabolites. Supplementary Data S17:32 serum metabolite markers Supplementary Data S18:p-value of Spearman correlation analysis. Supplementary Data S19:rho-value of Spearman correlation analysis.

Files

Categories

Non-Alcoholic Fatty Liver Disease, Metabolome Analysis

Licence